Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to: - Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus - The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics - The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus - To find out how safe and tolerable the sarilumab pretreatment is, in combination with REGN4018 and cemiplimab


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03564340
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email clinicaltrials@regeneron.com
Status Recruiting
Phase Phase 1/Phase 2
Start date May 21, 2018
Completion date June 21, 2026

See also
  Status Clinical Trial Phase
Completed NCT02195973 - Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer Phase 1
Not yet recruiting NCT05270720 - Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer Phase 1
Not yet recruiting NCT06070285 - Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Completed NCT02303912 - Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT01802749 - Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer Phase 3
Completed NCT02788708 - Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer Phase 1
Recruiting NCT05610735 - Combination Therapy for Recurrent Ovarian Cancer Phase 1/Phase 2
Withdrawn NCT02083536 - LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma Phase 1
Completed NCT03430518 - Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Phase 1
Recruiting NCT03618706 - Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer Phase 2
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT01851746 - A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer N/A
Active, not recruiting NCT06107868 - Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer Phase 1
Recruiting NCT06308406 - A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06365853 - A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression Phase 2
Completed NCT04718740 - A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer Phase 1
Active, not recruiting NCT05335993 - A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. Phase 2
Completed NCT01381861 - Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Phase 2
Not yet recruiting NCT05126342 - Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi Phase 2
Completed NCT02849353 - Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer Phase 1/Phase 2